Bisphenol A (BPA) is a high production volume chemical that is used in plastics and epoxy coatings. In 2015, California's Office of Environmental Health Hazard Assessment (OEHHA) added BPA to the Proposition 65 list of chemicals "known to cause reproductive toxicity" based on its Developmental and Reproductive Toxicant Identification Committee's (DART-IC) conclusion that BPA has been shown to cause female reproductive toxicity. A critical factor in determining compliance with Proposition 65 is a Maximum Allowable Dose Level (MADL), which is the exposure level at which a chemical would have no observable reproductive effect even if a person were exposed to 1000 times that level. We performed a comprehensive review of the literature, including the studies reviewed by DART-IC, and derived an oral MADL. Of all the studies we identified, Delclos et al. (2014) is of sufficient quality, has the lowest no observed effect level (NOEL), and results in the most conservative MADL of 157 mg/d. This is generally supported by other studies, including those that were considered by DART-IC. Also, the oral MADL provides a similar margin of safety as OEHHA's dermal MADL and other regulatory guidelines. Taken together, the scientific data support an oral MADL of 157 mg/d.
Introduction
Bisphenol A (BPA) is a high production volume chemical that has been used in plastics and epoxy coatings since the 1950s. In the 1990s, a number of studies raised concerns regarding BPA's safety. Since that time, thousands of studies have been conducted (e.g., reviewed by Goodman et al., 2009; EFSA, 2015; US FDA, 2008; . The vast majority of these, including several large, robust studies conducted in compliance with Good Laboratory Practice guidelines, have found no evidence that toxicity could occur at typical or even high-end human exposures, although some smaller studies (in particular, in vitro and other mechanistic studies) have reported some biological responses of unknown significance (e.g., Benachour and Aris, 2009; Zhang et al., 2014; Lawson et al., 2011) .
Regulatory agencies around the world have evaluated these BPA studies and their implications for human health over the last few decades using risk assessment methods. This includes comprehensive weight-of-evidence reviews of the available toxicity literature and exposures in the general population. Almost all have concluded that current exposures to BPA do not pose a human health risk (e.g., FSANZ, 2012; Aungst and Anderson, 2014; AIST RISS, 2011; Health Canada, 2008; JECFA, 2010; BfR, 2008) . In a 2015 comprehensive review and risk assessment, the European Food Safety Authority (EFSA) calculated a temporary Tolerable Daily Intake (t-TDI) for BPA of 4 mg/kg-d (EFSA, 2015) .
EFSA concluded that the highest estimates for BPA exposure from both dietary and non-dietary sources are three to five times lower than the t-TDI.
On May 11, 2015, California's Office of Environmental Health Hazard Assessment (OEHHA) added BPA to the Proposition 65 list of chemicals "known to cause reproductive toxicity" based on its Developmental and Reproductive Toxicant Identification Committee's (DART-IC) conclusion that BPA has been shown to cause female reproductive toxicity (OEHHA, 2015) , although neither a specific study nor a specific endpoint has been provided by OEHHA to support the listing.
A critical factor in determining compliance with Proposition 65 is an evaluation of whether the reasonably anticipated use of a product could result in an exposure above a Maximum Allowable Dose Level (MADL) (OEHHA, 2014) . A MADL is the exposure level at which a chemical would have no observable reproductive effect, even if a person were exposed to 1000 times that level. Proposition 65 requires that a MADL be based on the specific endpoint that supported the Proposition 65 listing. Despite not identifying a specific endpoint or study to support the listing, in 2015, OEHHA relied on a subcutaneous dosing study in sheep by Veiga-Lopez et al. (2013) to derive a dermal MADL. These investigators treated pregnant sheep subcutaneously from gestational day (GD) 30 to GD 90 with BPA, and assessed reproductive toxicity at 19 months of age. They observed an effect on the trajectory of follicle development at all doses.
OEHHA determined that the lowest observed effect level (LOEL) in this study was 0.05 mg/kg-day and divided this by 10 to establish a surrogate no observed effect level (NOEL) (OEHHA, 2016) . This NOEL was further adjusted using methods in accordance with the Proposition 65 regulations (i.e., by multiplying the NOEL by a standard female body weight [58 kg] and dividing by an uncertainty factor of 1000) (OEHHA, 2014) to derive a dermal MADL of 3 mg/d.
OEHHA has not published an oral MADL. Because it is not clear what the basis for the BPA Proposition 65 listing is, we derived an oral MADL based on "the most sensitive study deemed to be of sufficient quality" for specific endpoints that fall within the category of "female reproductive toxicity," which is consistent with the Proposition 65 regulations.
Methods
We identified BPA studies that were evaluated in three weightof-evidence reviews (Gray et al., 2004; Goodman et al., 2006 Goodman et al., , 2009 and in a more recent PubMed literature search limited to studies published between July 25, 2008 (the cutoff for the Goodman et al., 2009 review) , and December 1, 2016. We included studies if they were peer-reviewed, evaluated in vivo rodent findings, used oral doses 5 mg/kg-d, and examined female reproductive endpoints (either as primary or secondary endpoints). Several of the larger low dose studies also evaluated high doses (Delclos et al., 2014; Tyl et al., 2002 Tyl et al., , 2008 Stump et al., 2010) .
We only considered oral studies to avoid possible interpretation issues associated with first-pass metabolism of BPA and because they are more relevant for the calculation of an oral MADL compared to studies using other exposure routes. Specific endpoints we focused on include body and reproductive organ weights, perinatal characteristics, pubertal characteristics, teratogenic effects, and reproductive function. We only considered studies that evaluated either morphologically evident effects pertinent to reproduction or reproductive endpoints themselves. We did not consider biochemical effects, such as changes in endocrine activity or gene expression, because these are not toxic endpoints in and of themselves (as discussed by Goodman et al., 2009) . We included studies of all frequencies and durations of exposure with doses up to 5 mg/kg-d to ensure that no low-dose studies were excluded. We also included the 321 BPA studies identified by DART-IC (OEHHA, 2015) . In total, we considered all studies that were part of the DART-IC hazard identification materials, as well as additional studies that evaluated female reproductive toxicity that met the criteria discussed above.
In Section 25803, Proposition 65 indicates, "Animal bioassay studies for assessment shall meet generally accepted scientific principles, including the thoroughness of experimental protocol, the degree to which dosing resembles the expected manner of human exposure, the temporal exposure pattern, the duration of study, the purity of test material, the number and size of exposed groups, and the route of exposure and the extent of occurrence of effects." Because these guidelines are relatively non-specific, we assessed study quality based on criteria that are consistent with these and that have been used in previous evaluations (e.g., Goodman et al., 2014; Prueitt et al., 2014) , the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines (Kilkenny et al., 2010) , and other international research guidelines, such as those of the Organization for Economic Co-operation and Development (OECD) and World Health Organization (WHO) (OECD, 1998; WHO, 2009 ). These criteria include:
Appropriate female reproductive endpoints were evaluated (e.g., implantation sites, ovarian weights/histopathology, estrus cycle effects); Animals were randomized to treatment groups; There were at least five animals/sex/group; Valid, reliable, and sensitive methods were used to measure exposure with clear reporting of methods (e.g., authors describe dosing regimen, purity of test substance, source of test substance, administration route, and appropriateness of said route); Controls were utilized and appropriate (e.g., exposed to sterile vehicle) 1 ;
The authors described details of animals used (i.e., species, age, strain, where purchased from/bred), feeding/housing conditions (e.g., light/dark cycles, temperature, humidity, number of animals per cage, food and bedding), acclimation period, and sacrifice methods; Valid, reliable and sensitive methods were applied consistently across groups to assess and report outcomes; All results were presented (regardless of statistical significance); Details on sample handling and storage, and all assays, were provided; Details of study-related deaths were provided; and Appropriate statistical methods were used.
In addition to the criteria noted above, we also evaluated whether or not effects were consistent across the literature at specific doses, and whether studies showed a pattern of effect for each statistically significant endpoint.
After identifying what we considered to be the most appropriate, high-quality study, we used the following Proposition 65 equation to calculate an oral MADL based on the NOEL from that study:
MADL ðmg=dÞ ¼ NOEL ðmg=kg À dÞ Â BW ðkgÞ UF where: NOEL ¼ no observed effect level BW ¼ standard female body weight (58 kg) UF ¼ uncertainty factor (defined by statute as 1000)
Results
We identified 27 studies that met our quality inclusion criteria. After reviewing these studies, we determined that the recent study by Delclos et al. (2014) and earlier studies by Tyl et al. (2002 Tyl et al. ( , 2008 and Stump et al. (2010) were the most sensitive studies of sufficient quality for deriving an oral MADL.
1 Inclusion of a positive control has been recommended for low-dose BPA studies, due to differing sensitivities of animal species and strains to estrogenic effects (Richter et al., 2007) , although positive controls are not required in reproductive/ developmental guideline studies (OECD, 1998; US EPA, 1983; 1989). Delclos et al. (2014) conducted a 90-day subchronic study that evaluated the effects of BPA exposure on rat dams and their offspring at nine dose levels, including seven equally spaced doses by gavage between 2.5 and 2700 mg/kg-day. The authors also included two high-dose groups (100,000 and 300,000 mg/kg-day) that were expected to experience adverse effects, based on previous studies. Dams were dosed daily from GD 6 until the start of labor, and pups were dosed daily thereafter. The authors evaluated a wide variety of reproductive and developmental endpoints (Table 1 ). This study is particularly robust because it included a large number of animals in each dose group (~20), evaluated a wide range of doses (over five orders of magnitude), included both negative and positive controls (2 dose levels), evaluated internal BPA dosimetry, and was conducted under a protocol designed by a large group of diverse collaborators. It was also conducted in compliance with the US Food and Drug Administration (US FDA) Good Laboratory Practice (GLP) regulations (21 CFR, Part 58). Tyl et al. (2008) conducted a two-generation BPA reproductive toxicity study in mice. Dietary BPA was provided at doses of 3, 30, 300, 5,000, 50,000, or 600,000 mg/kg-d to both generations for the duration of the study. A wide variety of reproductive and developmental effects were evaluated, including adult mating, fertility and gestational indices, ovarian primordial follicle counts, estrous cyclicity, precoital interval, offspring sex ratios and postnatal survival, and reproductive organ weights and histopathology. Tyl et al. (2002) conducted a similar study; in which they dosed three generations of Sprague-Dawley rats with 1, 20, 300, 5,000, 50,000 or 500,000 mg/kg-d BPA. Both studies were conducted in compliance with OECD GLP regulations. Stump et al. (2010) conducted a developmental neurotoxicity dietary study in compliance with OECD and United States Environmental Protection Agency (US EPA) guidelines for the study of developmental neurotoxicity. Dams and their offspring were dosed via diet from GD 0 through lactation day 21 with 10, 100, 5,000, 50,000, or 150,000 mg/kg-d. In addition to neurodevelopmental toxicity endpoints, Stump et al. (2010) evaluated reproductive endpoints such as pregnancy rates, gestations lengths, and parturition endpoints. Delclos et al. (2014) and Tyl et al. (2008) used both negative (sham) and positive (e.g., estradiol, ethinyl estradiol [EE 2 ]) controls; Tyl et al. (2002) only used negative controls. Stump et al. (2010) did not include positive controls because there are no available data regarding whether behavioral and neurodevelopmental endpoints are sensitive to steroidal estrogens. Tyl et al. (2002 Tyl et al. ( , 2008 and Stump et al. (2010) did not observe any consistent reproductive effects from BPA exposure via the diet. Delclos et al. (2014) , who dosed animals via gavage, observed clear adverse effects for BPA at the two highest doses administered (i.e., 100,000 and 300,000 mg/kg-day BPA), with the majority of the effects occurring in females (Table 1 , Supplemental Tables 1e6). They also observed a few effects between 2.5 and 2700 mg/kg-day, but determined that they were not likely caused by BPA because they were observed sporadically across dose groups and were inconsistent across groups when compared to the observed effects of EE 2 (0.5 and 5.0 mg/kg-day) or high BPA doses (100,000 and 300,000 mg/ kg-day). The reproductive toxicity NOEL from the Delclos et al.
(2014) study is 2700 mg/kg-d, based on significantly increased levels of estradiol in females in the 100,000 mg/kg-d dose group.
Consistent with prior studies (e.g., see Mattison et al., 2014) , Delclos et al. (2014) , Tyl et al. (2008 Tyl et al. ( , 2002 , and Stump et al. (2010) found that BPA is weakly estrogenic (i.e., the observed effects for BPA at high doses were similar to the effects observed for positive EE 2 controls). While each of these four studies is of sufficient quality and could be used to develop an MADL, Delclos et al. (2014) has the lowest NOEL (2700 mg/kg-d) and is thus the most sensitive.
It is also the most robust in terms of number of animals, dose groups, and the use of positive and negative controls. It is also supported by the other three studies. Based on this NOEL, we calculated an oral BPA MADL of 157 mg/day.
Discussion
Almost without exception, regulatory agencies around the world have concluded that current human exposures to BPA do not pose a risk of reproductive effects based on robust risk assessments and reviews of the literature (e.g., FSANZ, 2012; Aungst and Anderson, 2014; AIST RISS, 2011; Health Canada, 2008; JECFA, 2010; BfR, 2008) . California has listed BPA as a reproductive toxicant under Proposition 65 based on a hazard assessment. OEHHA has not derived an oral MADL; here we derived an oral MADL of 157 mg/day, based on the study by Delclos et al. (2014) , which demonstrated effects only at exposures higher than reasonable high-end human exposures. This study is the "most sensitive study deemed to be of sufficient quality," as required by the Proposition 65 regulation for the derivation of a MADL.
US FDA extensively reviewed the Delclos et al. (2014) study and concluded: "The study was well conducted and each of the targeted parameters/end-points was thoroughly investigated, recorded and evaluated. In addition to a broad range for dose exposure (especially the low dose range), the use of the litter as the appropriate unit for data analysis, the strictly controlled micro-environment in the study, and in utero exposure of and direct-dosing to pups in this study all contributed to a robust assessment of potential adverse effects of BPA especially at doses that are closer to the low-dose human exposure scenario" (US FDA, 2014) . Despite this, a few scientists have suggested that the Delclos et al. (2014) study should not be used for a MADL derivation because of possible contamination of negative control treatments with BPA, an inappropriate analysis of estrous cyclicity, and findings of adverse effects on mammary glands at low doses (e.g., Hunt et al., 2012). However, (1) 300,000 mg/kg-day was the highest dose tested in the study.
these claims do not stand up to rigorous scientific scrutiny. Concerns about possible low-level BPA exposure in the negative controls are addressed by Delclos and Doerge (2014) , who indicated that, although the low-level exposures could potentially impact the ability to discern effects below 8 mg/kg-d, because no treatmentrelated effects were observed up to 2700 mg/kg-d (and effects were observed in high-dose BPA and positive control animals), this does not change the overall conclusions of the original study. Concerns about possible estrous cyclicity issues in control animals are similarly debunked by Delclos and Doerge (2014) . The same definition of "normal" estrous cyclicity was applied to all dose groups and, as expected, there were significant changes in both the high-dose BPA and positive controls (but not in the low dose BPA groups). Finally, regarding mammary gland hyperplasia, there were no significant differences between any dose group less than 300,000 mg/kg-d and controls. There were also no significant differences between average lesion severity for any BPA dose group under 2700 mg/kg-d and controls (Delclos et al., 2014; Felton et al., 2016) . (We also note that mammary gland hyperplasia in the 2700 mg/kg-d dose group is not relevant to the Proposition 65 reproductive endpoint analysis, as mammary gland hyperplasia is not an adverse reproductive effect.) Overall, the many strengths of the Delclos et al. (2014) study outweigh these factors and, even if these criticisms were valid, the Delclos et al. (2014) study would still be of sufficient quality to derive a MADL.
DART-IC considered many other studies when evaluating BPA and reproductive effects. This includes several studies with serious design and analysis limitations, including a lack of positive controls, small sample sizes, and a lack of background BPA exposure measurements (e.g., Kobayashi et al., 2010 Kobayashi et al., , 2012 Yoshida et al., 2004; Anderson et al., 2013; Kendig et al., 2012; van Esterik et al., 2014) . Because they were considered by DART-IC, several of these studies are discussed below, and their key findings are described in Supplemental Tables 1e6.
These studies include mechanistic animal studies by Ahmed et al. (2014) , Calhoun et al. (2014) , Christiansen et al. (2014) , Kundakovic et al. (2013) , Lee et al. (2013), and McCaffrey et al. (2013) . We found that the studies by Ahmed et al. (2014) , Calhoun et al. (2014) , Christiansen et al. (2014) , and Lee et al. (2013) are not of sufficient quality for deriving an MADL based on being mechanistic, reporting only sporadic effects, having small sample sizes, a lack of positive controls, or a lack of background BPA exposure measurements, and/ or having failed to appropriately account for litter effects. McCaffrey et al. (2013) investigated the mechanism for potential neurobehavioral effects on sexual differentiation, and Kundakovic et al. (2013) investigated a potential epigenetic mechanism for the effects of BPA on sexual differentiation, so neither of these studies provides data on endpoints that have known effects on reproduction (i.e., the endpoints are of unknown biological significance).
Another study DART-IC considered that reported reproductive effects at doses lower than those in Delclos et al. (2014) and Tyl et al. (2002 Tyl et al. ( , 2008 was conducted by Ziv-Gal et al. (2015) , who examined potential transgenerational effects of BPA following in utero exposure in FBV mice. F 0 dams were orally dosed from GD 11 until birth with vehicle, 0.5, 20, or 50 mg/kg-day BPA. A positive control treated with diethylstilbestrol (DES) (0.05 mg/kg-day) was also included, and F 1 , F 2 , and F 3 females were evaluated. Overall, no consistent BPA-related effects were observed for any of the endpoints examined, which included pregnancy rate, mating, fertility, pubertal onset, and litter size. However, the authors concluded that an effect on fertility index at one middle dose (0.5 mg/kg-day; no effect at the two higher doses) in the third generation might be related to BPA exposure and stated, "Collectively, these data suggest that BPA exposure affects reproductive function in female mice and that some effects may be transgenerational in nature" (Ziv-Gal et al., 2015 ). This conclusion is not supported by the lack of effects observed in the F 1 and F 2 females as well as the lack of effect at the higher exposure levels. It is also not consistent with the lack of effects on F 1 and F 2 female fertility reported in robust guideline studies that also evaluated multigenerational BPA exposures (Tyl et al., 2002 (Tyl et al., , 2008 .
Several studies reviewed by DART-IC evaluated the potential impact of BPA on the ovaries. These smaller animal toxicity studies reported effects of unknown biological significance in the ovaries of females of dams dosed with BPA (e.g., Hunt et al., 2012) . If these effects were either adverse themselves or precursors to adverse effects, they should have occurred and caused downstream effects on functional endpoints in multigenerational studies that evaluated ovarian histopathology and other reproductive endpoints. Yet these effects are not seen in large studies conducted in compliance with regulatory guidelines. For instance, Tyl et al. (2008) found no effects on fertility, ovarian weights, histopathology, or primordial follicle counts in a three-generation mouse study at doses of 50,000 mg/kg-day BPA and below. Similarly, Tyl et al. (2002) reported a reproductive no observed adverse effect level (NOAEL) of 50,000 mg/kg-day BPA in rats.
Taken together, of all the studies DART-IC reviewed, we identified none of sufficient quality that demonstrated effects below those reported in Delclos et al. (2014) .
In addition to reviewing reproductive toxicity studies, we determined how the oral MADL we calculated compared to the dermal MADL calculated by OEHHA. In humans, BPA is almost completely converted to inactive metabolites, primarily by the liver, upon ingestion (Volkel et al., 2002; Teeguarden et al., 2015; Thayer et al., 2015) . Studies in humans (Volkel et al., 2002 (Volkel et al., , 2005 Teeguarden et al., 2011) and non-human primates (Doerge et al., 2010; Taylor et al., 2011; Tominaga et al., 2006) indicate that oral bioavailability of active BPA is significantly impacted by first-pass metabolism, ranging from 0.2 to 1% of the total dose. Of these studies, the most recent and robust study quantifying first-pass metabolism in humans, conducted by Teeguarden et al. (2015) , reported an average maximum concentration of active BPA in serum as 0.2% of the total dose. This study utilized the most sensitive methods (i.e., had the lowest limits of detection) and best reflects bioavailability of active BPA in humans after oral exposure. This value is also the same as that which we derived from comparing integral concentration over time profiles (i.e., area under the curve [AUC]) from oral and subcutaneous exposure to 10 mg/kg bw BPA in cynomolgus monkeys (Tominaga et al., 2006) , and lower than that derived from Doerge et al. (2010) , who found slightly higher estimates (0.94%) of absolute bioavailability of active BPA in a study of rhesus monkeys exposed to 100 mg/kg bw BPA via oral and i.v. routes. 2 Multiplying this dose by 58 kg and dividing by an uncertainty factor of 1000 leads to an MADL of 145 mg/d, which is 2 This calculation is based on the assumption that the metabolism of BPA following subcutaneous administration is similar in sheep and humans. This assumption was made by CalOEHHA in its MADL derivation (CalOEHHA, 2016) and is supported by virtually identical Km values of 36 for sheep and 37 for humans, respectively (Nair and Jacob, 2016; Bennett, 1973 EFSA calculated a t-TDI based on a conservative, high-quality study reviewed above (Tyl et al., 2008) . Specifically, it calculated that the BPA dose needed to cause a 10% change in the mean relative kidney weight in mice would be 8960 mg/kg-d (EFSA, 2015) .
Based on differences in how mice and humans metabolize BPA, EFSA converted this dose to an oral equivalent dose for humans of 609 mg/kg-d. EFSA then divided this value by 25 to take into account additional differences between species and between individual people, and a factor of six to take into account the uncertainty in the database regarding effects on the mammary gland and reproductive, neurobehavioral, immune, and metabolic systems. Dividing 609 mg/kg-d by the total uncertainty (25 Â 6) resulted in the t-TDI of 4 mg/kg-d. This value is equivalent to 232 mg/d in a 58 kg woman.
While this value is extremely conservative and based on a robust study, it is still a bit less conservative than the MADL we calculated.
A limitation of our analysis is that we used a subchronic study to calculate an MADL designed for chronic exposure. Also, US FDA (2014) concluded that this study should not be used to choose points of departure for risk assessment because it was designed to evaluate low dose exposures. However, US FDA's reasoning is that effects were only noted in the animals dosed with 100 and 300 mg/ kg-d BPA, which are orders of magnitude above the low doses, thus making the NOAEL extremely conservative. Also, high-quality, chronic, multi-generational studies (i.e., Tyl et al., 2002 Tyl et al., , 2008 Stump et al., 2010) did not observe effects at exposures as low as Delclos et al. (2014) did, and the MADL we calculated is similar to MADLs we calculated based on the OEHHA dermal MADL and the NOAEL identified by US FDA, as well as the EFSA t-TDI ( Table 2 ). All of these are based on many conservative assumptions, and the latter two are based on multi-generation studies.
Conclusion
Of all the studies we identified, Delclos et al. (2014) is the most sensitive study of sufficient quality for the derivation of an oral MADL. That is, Delclos et al. (2014) has the lowest NOEL and results in the most conservative value for protection against female reproductive effects. The MADL we calculated using this NOEL is supported by other high quality studies we considered (e.g. Tyl et al., 2002 Tyl et al., , 2008 Stump et al., 2010) , as well as studies that were considered by DART-IC. Also, this oral MADL provides a similar margin of safety as OEHHA's dermal MADL and EFSA's t-TDI.
Taken together, the evidence supports an oral MADL of 157 mg/d.
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